Agitation by Suffocation: How Hypoxia Activates Innate Immunity via the Warburg Effect  by Wen, Haitao & Ting, Jenny P.-Y.
Cell Metabolism
PreviewsAgitation by Suffocation:
How Hypoxia Activates Innate Immunity
via the Warburg EffectHaitao Wen1 and Jenny P.-Y. Ting1,2,*
1Lineberger Comprehensive Cancer Center
2Department of Microbiology and Immunology
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
*Correspondence: jenny_ting@med.unc.edu
http://dx.doi.org/10.1016/j.cmet.2013.05.016
A hypoxic microenvironment can enhance the function of innate immune cells; however, the mechanisms
remain unclear. Tannahill et al. (2013) find that in macrophages, the accumulation of succinate, an interme-
diatemetabolite of the tricarboxylic acid cycle, stabilizes the transcription factor HIF-1a, leading to activation
of the proinflammatory cytokine IL-1b.Acute inflammatory response against
invading pathogens, injury, or toxic
agents frequently occurs in a microenvi-
ronment with lower oxygen level called
hypoxia. Hypoxia is caused by vascular
damage, edema, and increased meta-
bolic activities of infectious pathogens
and host cells. Therefore, an efficient im-
mune response within a hypoxic environ-
ment is a key step in the prevention of
infection. Indeed, evidence suggests
that innate immune cells such as macro-
phages and neutrophils use hypoxia-
inducible factor (HIF), a central transcrip-
tional regulator of hypoxic responses,
to enhance their immune functions,
including cytokine production and micro-
bicidal function (Nizet and Johnson,
2009). HIF is a heterodimeric helix-loop-
helix transcription factor and is known to
regulate the expression of more than
100 genes that are involved in a plethora
of host stress responses triggered by
hypoxia in a variety of cell types. HIF-1a
and HIF-2a, two hypoxia-inducible a sub-
units, have been shown to play essential
roles in innate immune cell-mediated
host defense function and the inflamma-
tory response (Cramer et al., 2003; Peys-
sonnaux et al., 2005, 2007). Despite
cumulative evidence showing an essential
role of HIF in innate immune response, the
detailed molecular mechanism by which
HIF controls immune function needs
more clarity. Specifically, although it is
clear that lipopolysaccharide (LPS)-
induced macrophage activation en-
hances Hif1a gene transcription in an
IKKb/NF-kB signaling-dependent manner
(Rius et al., 2008), HIF-1a protein is very814 Cell Metabolism 17, June 4, 2013 ª2013unstable (Nizet and Johnson, 2009) and
is marked for degradation by the protea-
some by prolyl hydroxylase (PHD). How
newly synthesized HIF-1a protein is stabi-
lized in activated macrophages remains
unknown. A recent study by O’Neil and
colleagues (Tannahill et al., 2013) ad-
dresses this issue by showing that succi-
nate, an intermediate metabolite of the
tricarboxylic acid cycle (TCA), accumu-
lates in LPS-stimulated macrophages,
and this accumulation stabilizes HIF-1a
protein, which then activates Il1b tran-
scription to initiate innate immunity
(Figure 1) (Tannahill et al., 2013).
To investigate the mechanisms by
which HIF-1a is stabilized in macro-
phages during immune responses, Tan-
nahill et al. performed metabolomics
screening analyses and found that treat-
ment of macrophages with LPS induced
a ‘‘Warburg effect,’’ which is a metabolic
reprogramming process common to can-
cer cells wherein mitochondrial oxidative
phosphorylation (OXPHOS) is reduced
while aerobic glycolysis increases. This
observation is consistent with a previous
study showing enhanced glycolysis in
classically activated macrophages
(Rodrı´guez-Prados et al., 2010). Interest-
ingly, the authors found that the LPS-
induced reduction in OXPHOS leads to
the accumulation of TCA intermediate
metabolites, specifically succinate. Suc-
cinate moves freely between mitochon-
dria and cytosol via the dicarboxylic acid
transporter in the mitochondrial inner
membrane and the voltage-dependent
anion channel (VDAC) in themitochondrial
outer membrane. Previous studies in can-Elsevier Inc.cer cells have shown that excessive cyto-
solic succinate suppresses the catalytic
activity of PHD and thereby promotes
accumulation of HIF-1a (Selak et al.,
2005). HIF-1a stabilization leads to en-
hanced HIF-1a-dependent target gene
transcription, which includes glucose
transporters and glycolytic enzymes.
Importantly, Tannahill et al. find that this
succinate- HIF-1a axis is induced by
LPS in macrophages and leads to en-
hanced glucose usage and glycolysis
rate. Concomitantly, they also find that
activity of the pentose phosphate path-
way and its downstream products are
also increased, which helps cells meet
the demand for increased energy produc-
tion and nucleotide synthesis. In addition
to glycolytic targets, Tannahill et al. iden-
tify IL-1b, a potent proinflammatory cyto-
kine, as a direct transcriptional target of
HIF-1a. After LPS stimulation, HIF-1a
directly binds to a conserved binding
site on the promoter region of Il1b gene
in both human and mouse macrophages.
This binding is essential for optimal Il1b
gene transcription in response to LPS
stimulation. HIF-1a-mediated cytokine
gene transcription is specific to Il1b, but
not genes encoding other proinflamma-
tory cytokines such as Tnfa and Il6.
How is excessive succinate generated
under conditions of dysfunctional TCA cy-
cle in LPS-activated macrophages? Mito-
chondrial glutamine catabolism refuels
the TCA cycle and contributes to a num-
ber of metabolic pathways. Glutamine
can be metabolized via glutaminase to
glutamate and NH4
+, which is further con-
verted to the TCA cycle intermediate
Figure 1. Mitochondria-Derived Succinate Promotes IL-1b Production by Stabilizing HIF-1a
in LPS-Activated Macrophages
In unstimulated macrophages, hypoxia-inducible factor-1a (HIF-1a) is unstable and undergoes contin-
uous degradation via the ubiquitin-proteasome pathway. The degradation process requires HIF-1a
hydroxylation mediated by prolyl hydroxylase (PHD). When macrophages are activated by lipopolysac-
charide (LPS), a metabolic reprogramming occurs, leading to the accumulating of succinate, an interme-
diate metabolite of mitochondrial tricarboxylic acid cycle. Excessive succinate inhibits PHD activity
through product inhibition and stabilizes the newly synthesized HIF-1a. HIF-1a then activates a number
of genes, including the gene encoding the proinflammatory cytokine interleukin-1b (IL-1b), as well as those
involved in glycolysis. TLR4, Toll-like receptor 4.
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Previewsa-ketoglutarate (a-KG), an upstream
metabolite for succinate production.
Therefore, increased glutamine use could
provide the essential source for succinate
production when general TCA cycle activ-
ity is depressed. Indeed, by tracing the
flux of radiolabeled glutamine, Tannahill
et al. observed a 14-fold increase in gluta-
mine-derived succinate production in
response to LPS stimulation, which is
largely through the a-KG-succinate
pathway, with the glutamine-GABA
(g-aminobutyric acid) shunt pathway
playing a partial role in succinate accu-
mulation (Tannahill et al., 2013). The
increased glutamine use is due to
increased expression of one of the gluta-
mine transporters, solute carrier family 3
member 2 (SLC3A2) in LPS-activated
macrophages. It will be interesting to
test if the activity of glutaminase is also
enhanced by LPS stimulation and contrib-
utes to glutamine metabolism.
Identification of the succinate-HIF-
1a-IL-1b axis in activated macrophagesmay provide additional mechanistic
insight for both host defense response
and autoimmune diseases. One common
feature among various inflammatory and
infectious diseases is a lowered oxygen
content in the local environment. There-
fore, the upregulation of HIF-1a in newly
recruited macrophages may provide a
survival advantage that leads to enhanced
host defense against invading pathogens.
On the other hand, this same advantage in
autoimmune diseases such as multiple
sclerosis and rheumatoid arthritis may
exacerbate T cell activation and cytokine
production through IL-1b. In contrast to
succinate, a-KG promotes PHD enzy-
matic activity and depletesHIF-1a (MacK-
enzie et al., 2007). Therefore, theopposing
effects of a-KG and succinate on HIF-
1a-IL-1b signaling provide new therapeu-
tic targets and strategies for treating
different inflammatory diseases depend-
ing on the desired outcome.
The mitochondrion has recently
emerged at the forefront of host innate im-Cell Metabolismmune response against invading patho-
gens including viruses and bacteria.
Although it is well established that the
mitochondrion provides an ideal platform
for the assembly of multiple innate
signaling complexes, such as MAVS-
RIG-I antiviral, ECSIT-TRAF6 antibacte-
rial, and NLRP3 inflammasome immune
complex (West et al., 2011), it is reason-
able to hypothesize that the mitochon-
drion can regulate immune signaling by
additional mechanisms, since this organ-
elle is the essential powerhouse of the
cell andprovides themajority of intermedi-
ate metabolites for many basic biological
processes. The identification ofmitochon-
dria-derived succinate as an inflammatory
signal sheds light on a newmechanism by
which mitochondria control the cytosolic
signaling pathway and gene transcription
through the modulation of cell stress re-
sponses in the immunesystem. Therefore,
the findings of Tannahill et al. suggest
there may be therapeutic potential in tar-
geting mitochondrial metabolic pathways
in inflammation-associated diseases.
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